News

FDA Approves Generic Versions of Singulair


 

The Food and Drug Administration has approved the first generic versions of the leukotriene receptor antagonist Singulair to control asthma and relieve allergies. Singulair (montelukast sodium) is designed to treat symptoms in both adults and children.

For more information, visit the FDA's website.

Recommended Reading

Cancer More Common in People With Sleep Apnea
MDedge Internal Medicine
Adaptive Servoventilation Bests CPAP Over Time
MDedge Internal Medicine
Post-MI Rehospitalization Rate Has Not Declined Since 1987
MDedge Internal Medicine
Immunocompromised Adults Advised to Receive PCV13 Vaccine
MDedge Internal Medicine
Erythromycin Reduces Bronchiectasis Exacerbations, Antibiotic Resistance
MDedge Internal Medicine
CPAP Improves Mood in Sleep Apnea Patients
MDedge Internal Medicine
Reflux-Associated Oxygen Desaturation Flags Pulmonary GERD
MDedge Internal Medicine
Sleep Problems May Increase Risk for Dementia
MDedge Internal Medicine
Pertussis Epidemic in Washington: Teen Booster, Adult Vaccination Key
MDedge Internal Medicine
Twice-Daily Inhaled Anticholinergic Approved for COPD
MDedge Internal Medicine